U.S. Metals and Mining Stock News

NYSE:TGLS
NYSE:TGLSBuilding

Is Tecnoglass (TGLS) Pricing Look Attractive After A 35% One-Year Share Price Decline

This article examines whether Tecnoglass is attractively priced or a potential value trap at its current level by walking through what the latest data indicates about the stock's valuation. The share price last closed at US$45.74, with returns of 4.7% over the past week, 0.1% over the past month, a 12.1% decline year to date, and a 35.6% decline over the last year, compared with an 8.2% three year return and a 274.0% return over five years. Recent pricing moves sit alongside ongoing investor...
NasdaqCM:OBT
NasdaqCM:OBTBanks

3 Undervalued Small Caps With Insider Buying Across Regions

Over the last 7 days, the United States market has risen by 4.2%, contributing to a substantial 29% climb over the past year, with earnings forecasted to grow by 16% annually. In this environment, identifying stocks that are both undervalued and have insider buying can present intriguing opportunities for investors seeking potential growth within small-cap sectors.
NYSE:BTGO
NYSE:BTGOCapital Markets

April 2026's Top Growth Stocks With Strong Insider Ownership

The United States market has experienced a notable upswing, climbing 4.2% in the last week and showing a robust 29% increase over the past year, with earnings anticipated to grow by 16% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those most familiar with the business's potential and operations.
NYSE:YSG
NYSE:YSGPersonal Products

GoPro Leads The Charge With 2 Other Penny Stocks

The market has climbed 4.2% in the last 7 days and is up 29% over the past year, with earnings forecast to grow by 16% annually. For investors interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value when backed by strong financials. This article will explore three penny stocks that stand out for their financial strength and potential long-term promise.
NasdaqGS:TRST
NasdaqGS:TRSTBanks

3 Undiscovered Gems In The US Market Backed By Solid Fundamentals

The United States market has shown impressive performance recently, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are expected to grow by 16% annually. In this environment, stocks with solid fundamentals and growth potential stand out as promising opportunities for investors seeking undiscovered gems.
NasdaqGS:AFYA
NasdaqGS:AFYAConsumer Services

3 Top Dividend Stocks Yielding Up To 4.7%

The United States market has shown impressive growth, rising 4.2% over the last week and 29% over the past year, with earnings expected to grow by 16% annually. In this thriving environment, identifying strong dividend stocks that offer both stability and attractive yields can be a key strategy for investors seeking consistent income alongside potential capital appreciation.
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

US Stock Market Today S&P 500 Futures Edge Higher As Rate Worries Ease

The Morning Bull - US Market Morning Update Tuesday, Apr, 14 2026 E-mini S&P 500 futures are pointing slightly higher this morning, with a gain of about 0.2% as investors weigh softer inflation signals against signs of strain in housing. The US 10 year Treasury yield is around 4.29%, which suggests some easing of interest rate fears as Iran peace talk hopes cool expectations of future price spikes. At the same time, March existing home sales are at a 9 month low of 3.98 million annualized,...
NYSE:MS
NYSE:MSCapital Markets

Is It Too Late To Consider Morgan Stanley (MS) After A 70% One-Year Rally?

If you are wondering whether Morgan Stanley at around US$181 per share still offers value or is starting to look stretched, the key is to separate price excitement from underlying worth. The stock's recent returns, including 8.8% over 7 days, 17.0% over 30 days and 70.5% over 1 year, along with a relatively flat year to date move of a 0.4% decline, suggest the market has been reassessing the story over different time frames. Recent coverage has focused on Morgan Stanley as a major global...
NYSE:JEF
NYSE:JEFCapital Markets

Is It Too Late To Consider Jefferies Financial Group (JEF) After Its Recent Share Price Rebound

Wondering if Jefferies Financial Group, at around US$46 per share, still offers value or if most of the opportunity is already reflected in the price. The stock has moved sharply in the short term, with a 10.1% return over 7 days and 27.1% over 30 days, set against a year-to-date return of a 27.2% decline and a 1-year return of 8.7% that sits within a longer 3-year return of 60.7% and 5-year return of 71.7%. These moves sit alongside ongoing interest in capital markets and corporate...
NasdaqGS:FAST
NasdaqGS:FASTTrade Distributors

Fastenal (FAST) Earnings Growth And 15.3% Margin Test Rich Valuation Narrative

Fastenal (FAST) just posted its Q1 2026 scorecard, with recent quarterly numbers showing Q4 2025 revenue of about US$2.0b and basic EPS of US$0.26, alongside trailing twelve month basic EPS of US$1.10 on revenue of roughly US$8.2b. The company has seen revenue move from US$1.82b in Q4 2024 to about US$2.03b in Q4 2025, while quarterly basic EPS shifted from US$0.23 to US$0.26 over the same period, setting up this latest report against a backdrop of steady top line and per share earnings. With...
NYSE:MO
NYSE:MOTobacco

Altria’s On Plus Launch Tests FDA Program And Smoke Free Strategy

Altria Group (NYSE:MO) is rolling out its on! PLUS nicotine pouches nationally across the U.S. on! PLUS is the first product cleared under the FDA's pilot accelerated review program for tobacco products. The launch comes as competition in the U.S. nicotine market intensifies and regulatory oversight stays active. Altria is best known for its U.S. cigarette and oral tobacco businesses, and the on! PLUS launch signals a stronger push into smoke free nicotine products. The FDA's pilot...
NYSE:MLM
NYSE:MLMBasic Materials

Congress Member Purchase Highlights Valuation And Momentum At Martin Marietta Materials

Representative April McClain Delaney recently bought shares of Martin Marietta Materials (NYSE:MLM). The transaction involves a sitting member of Congress, drawing attention to the company and its current valuation. The purchase comes as Martin Marietta Materials trades around $635.29 per share. Martin Marietta Materials, trading on the NYSE under the ticker MLM, sits at a share price of about $635.29. The stock has returned 6.2% over the past week, 8.8% over the past month, and 27.0% over...
NasdaqGS:SRRK
NasdaqGS:SRRKBiotechs

What Scholar Rock Holding (SRRK)'s FDA-Aligned Apitegromab BLA Resubmission Means For Shareholders

In late March 2026, Scholar Rock announced it had resubmitted its Biologics License Application to the FDA for apitegromab in spinal muscular atrophy, incorporating both the Catalent Indiana facility and a second U.S.-based fill-finish site in line with recent agency guidance. This resubmission, following a prior Complete Response Letter tied to manufacturing inspections rather than apitegromab itself, shifts regulatory focus back to the drug’s clinical profile and supply-chain readiness...
NYSE:ECVT
NYSE:ECVTChemicals

Ecovyst (ECVT) Is Up 9.1% After Earnings Beat And 2026 EPS Guidance Update Has The Bull Case Changed?

Ecovyst recently reported quarterly earnings that came in ahead of analyst expectations and issued full-year 2026 EPS guidance in the US$0.45–US$0.65 range, prompting several brokerages to reaffirm or upgrade their views on the company’s outlook. This combination of an earnings beat and clearer profit guidance has sharpened the focus on how Ecovyst’s fundamentals align with assessments that its shares may be trading at a premium to intrinsic value. We’ll now explore how Ecovyst’s...
NasdaqGS:ALLO
NasdaqGS:ALLOBiotechs

Why Allogene Therapeutics (ALLO) Is Up 16.8% After Early ALPHA3 MRD Clearance Data And What's Next

In April 2026, Natera highlighted interim futility analysis from Allogene Therapeutics’ registrational ALPHA3 trial, where its off‑the‑shelf anti‑CD19 CAR T candidate cema‑cel achieved molecular residual disease clearance in a majority of treated large B‑cell lymphoma patients and showed deep reductions in plasma ctDNA compared with observation alone. Because ALPHA3 is the first MRD‑guided randomized trial in this lymphoma setting, these early data not only support cema‑cel’s potential role...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Assessing Harrow (HROW) Valuation As Heavy Insider Selling Tests The Undervaluation Story

Insider selling puts Harrow (HROW) under the microscope Heavy insider selling at Harrow (HROW) has caught investor attention after company insiders sold about US$8.1 million of stock over the past 3 months, with no reported insider purchases. This activity comes as Harrow shares recently fell 3.6% to US$35.93. At the same time, external models such as GuruFocus’s GF Value suggest the stock may be modestly undervalued, creating a tension between insider behavior and valuation signals. See our...
NYSE:RERE
NYSE:RERESpecialty Retail

Assessing ATRenew (RERE) Valuation As AI Model Downgrade Highlights Cash Flow And Margin Concerns

ATRenew (RERE) is back in focus after AI driven models downgraded the stock, citing negative operating cash flow, compressed gross margins, weak technical signals, and a valuation that appears elevated relative to current profitability. See our latest analysis for ATRenew. Despite the downgrade, ATRenew’s recent 1 day share price return of 5.38% to US$4.70 and 7 day share price return of 5.15% sit against a weaker 30 and 90 day share price trend. At the same time, the 1 year total shareholder...